Understanding CIPN & CICI
A Critical Challenge in Cancer Treatment
Each year, hundreds of thousands of cancer patients face the debilitating side effects of their lifesaving chemotherapy.
Nearly 50% of patients receiving taxane-based therapy must choose between risking sub-optimal cancer treatment outcomes associated with reducing chemotherapy dosage or the painful and debilitating impact of CIPN and CICI –conditions for which there are no effective treatments.
We are developing OSM-0205 to address the urgent need of patients faced with the challenges of CIPN and CICI (commonly known as “chemo brain”).
OSM-0205:
Easing the Journey for Cancer Patients
With a dual focus on physical and cognitive well-being, our preclinical studies reveal a promising path.
Our groundbreaking approach aims to prevent CIPN and CICI before they impact patients – paving the way for optimal chemotherapy dosing and enhanced patient outcomes.
OSM-0205, delivered intravenously just before chemotherapy, targets the essential interaction that initiates the calcium surge – preventing the cascade of neuronal damage leading to CIPN and CICI.
Currently there are no effective treatments for CIPN
Targeting the Unseen Impact of Taxanes
CIPN impacts up to 80% of breast cancer patients receiving taxane-based chemotherapy. Up to 360,000 patients each year are faced with this risk.
In nonclinical studies, our lead drug, OSM-0205, has demonstrated the ability to prevent neuronal damage associated with CIPN.
The need for therapy to address this debilitating condition is clear. At Osmol, we are dedicated to providing the first treatment option with the potential to block the neuronal damage caused by CIPN before it starts.
The impact of CIPN on patient outcomes and Osmol's solution
WATCH NOW >
